A small Palo Alto, CA-based biotech has garnered some fresh attention for itself after touting the results of a small Phase I study designed to test its lead drug by measuring its impact on a key biomarker for Lou Gehrig's disease, or amyotrophic lateral sclerosis. While most developers focus their Phase I studies entirely on safety and tolerability, Neuraltus chose to also gauge the fluctuation of blood levels of the biomarker--which was not disclosed--24 hours after dosing. The developer, which the San Francisco Business Times notes is hoping to use the data to help woo new investors, recruited 32 patients for the study. Report